CareDx sees FY24 revenue $279M-$280M, consensus 276.43M

Testing Services patient results grew for the second quarter in a row to approximately 39,900, an increase of 4% as compared to the third quarter of 2023. Fourth quarter revenue for Testing Services is expected to be between $46M and $47M, a decrease of 3% as compared to the third quarter of 2023, which included one-time items previously discussed during third quarter earnings call. Full year revenue for Patient and Digital Solutions is expected to be approximately $37M eliminary revenue for the three months ended December 31 is expected to be between $65M and $66M, a decrease of approximately 3% compared with $67.2 M in the third quarter of 2023. Testing services revenue for the fourth quarter is expected to be between $46M and $47 M, compared with $47.8 million in the third quarter of 2023 and compared with $65.4 million in the same period in 2022. Total AlloSure and AlloMap patient results provided in the fourth quarter were approximately 39,900. Patient and Digital Solutions revenue for the fourth quarter is expected to be $9.7 million, compared to $8.4 million in the same period in 2022. Product revenue for the fourth quarter is expected to be $9.2 million, compared to $8.6 million in the same period in 2022.